Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Short Bowel Syndrome: later-stage trial registry
5 of 18 indexed Short Bowel Syndrome trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 5 currently recruiting · #953 of 28,707 conditions by registered trial count
Short Bowel Syndrome: 18 US clinical trials tracked, 5 recruiting.
Short Bowel Syndrome is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Zealand Pharma, running 4 of these trials.
Enrollment posture brief
Registry condition short-bowel-syndrome
OPEN 5 | RECR 28% | LATE 10 | EARLY 3 | RANK #953 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Diabetic Peripheral Neuropathy (28% recruiting · 18 trials)
Short Bowel Syndrome lists 5 open slots (28% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Short Bowel Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Short Bowel Syndrome is recruiting below its size-band peers.
5 of 18 indexed trials (27.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Short Bowel Syndrome research.
Zealand Pharma accounts for 4 of 18 trials (22.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Short Bowel Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 88 among the 18 trials that report a genuine target (sentinel values excluded). 11 of those (61.1%) plan for fewer than 100 participants.
-
Short Bowel Syndrome research is mostly interventional.
15 interventional and 3 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Zealand Pharma
NCT07197944
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
Eclipse Regenesis
NCT05535361
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
Boston Children's Hospital
NCT03530852
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
Hanmi Pharmaceutical Company Limited
NCT04775706
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
Lindsey Russell, MD
NCT06326645
Registry for Participants With Short Bowel Syndrome
Shire
NCT01990040
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
VectivBio
NCT05018286
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Zealand Pharma
NCT03905707
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Zealand Pharma
NCT04881825
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
VectivBio
NCT04627025
Pediatric Teduglutide Registry
Boston Children's Hospital
NCT04832087
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
Zealand Pharma
NCT03690206
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
Shire
NCT00930644
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
Shire
NCT00081458
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
Shire
NCT02954458
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
Wake Forest University
NCT01306838
Measurement of Body Composition by Air Displacement Plethysmography in Pediatric Intestinal Failure Patients
Christopher Duggan
NCT02561819
rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
Lynn Malec
NCT02355743
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 9 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Short Bowel Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Short Bowel Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Short Bowel Syndrome page
18 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Short Bowel Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zealand Pharma sponsors the most Short Bowel Syndrome trials on record, review their full trial history before evaluating a specific study. See Zealand Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Short Bowel Syndrome condition card totals 18 registered trials; most-linked intervention Placebo; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.